Patent 12121594 was granted and assigned to International Centre for Genetic Engineering and Biotechnology on October, 2024 by the United States Patent and Trademark Office.
A protein selected from the group consisting of Chrdl1, Fam3c, Fam3b and a fragment thereof, or a polynucleotide encoding therefor, for use in treating or reducing the risk of heart disease.